Login to Your Account

NitroMed Stops BiDil Trial Early On Positive Preliminary Data

By Kim Coghill

Tuesday, July 20, 2004
NitroMed Inc.'s stock soared 73.1 percent Monday when the firm suggested it could launch BiDil for African-Americans with heart failure one year ahead of schedule, after stopping a confirmatory trial due to favorable preliminary results. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription